View Filter All NewsPress Release Years All Years202120202019201820172016201520142013201220112010 Apply Press Release | June 11, 2021 Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting READ MORE Press Release | June 10, 2021 Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency READ MORE Press Release | June 09, 2021 Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations READ MORE Press Release | May 20, 2021 Vertex Announces EMA and MHRA Regulatory Applications For the Use of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children 6-11 Years Old READ MORE Pagination Current page 1 Page 2 Page 3 Next page Next
